Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on Generalized Modules for Membrane Antigens (GMMA)

3 Apr 2014

Abstract excerpt

INTRODUCTION: Neisseria meningitidis causes epidemics of meningitis in sub-Saharan Africa. These have mainly been caused by capsular group A strains, but W and X strains are increasingly contributing to the burden of disease. Therefore, an affordable vaccine that provides broad protection against meningococcal disease in sub-Saharan Africa is required. METHODS: We prepared Generalized Modules for Membrane...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial Infections and Vaccines
Share to Complement system in diseases
Share to Virology and Viral Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24704334
DOI: 10.1016/j.vaccine.2014.03.068

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on Generalized Modules for Membrane Antigens (GMMA)PMID 24704334Read ↗

Characterization of vaccine antigens of meningococcal serogroup W isolates from Ghana and Burkina Faso from 2003 to 2009Semantic proximity Read ↗

Meningococcal Factor H–Binding Protein Variants Expressed by Epidemic Capsular Group A, W‐135, and X Strains from AfricaSemantic proximity Read ↗

Meningococcal Factor H Binding Proteins in Epidemic Strains from Africa: Implications for Vaccine DevelopmentSemantic proximity Read ↗

Meningococcal Outer Membrane Vesicle Vaccines Derived from Mutant Strains Engineered To Express Factor H Binding Proteins from Antigenic Variant Groups 1 and 2Semantic proximity Read ↗

A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccineSemantic proximity Read ↗

Characterization of O-antigen delivered by Generalized Modules for Membrane Antigens (GMMA) vaccine candidates against nontyphoidal Salmonella.Semantic proximity Read ↗

A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trialSemantic proximity Read ↗

The Development of a Vaccine Against Meningococcus B Using Reverse VaccinologySemantic proximity Read ↗

Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.Semantic proximity Read ↗

Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome SequencingSemantic proximity Read ↗

From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccineSemantic proximity Read ↗

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.